MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer’s disease granulovacuolar degeneration bodies

被引：0
|
作者：
Harald Lund
Elin Gustafsson
Anne Svensson
Maria Nilsson
Margareta Berg
Dan Sunnemark
Gabriel von Euler
机构：
[1] iMed,Department of Neuroscience
[2] CNS and Pain Södertälje,Department of Clinical Neuroscience
[3] AstraZeneca Research and Development,undefined
[4] Center for Molecular Medicine,undefined
[5] Karolinska Institutet,undefined
来源：
Acta Neuropathologica Communications | / 2卷
关键词：
Alzheimer’s disease; MARK; Phosphorylation; Granulovacuolar degeneration bodies; Tau;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies
    Lund, Harald
    Gustafsson, Elin
    Svensson, Anne
    Nilsson, Maria
    Berg, Margareta
    Sunnemark, Dan
    von Euler, Gabriel
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2014, 2
  • [2] Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer’s disease treatment
    Wenchao Sun
    Seongsoo Lee
    Xiaoran Huang
    Song Liu
    Mohammed Inayathullah
    Kwang-Min Kim
    Hongxiang Tang
    J. Wesson Ashford
    Jayakumar Rajadas
    Scientific Reports, 6
  • [3] Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment
    Sun, Wenchao
    Lee, Seongsoo
    Huang, Xiaoran
    Liu, Song
    Inayathullah, Mohammed
    Kim, Kwang-Min
    Tang, Hongxiang
    Ashford, J. Wesson
    Rajadas, Jayakumar
    SCIENTIFIC REPORTS, 2016, 6
  • [4] Modulatory Role of Anti-Tau Antibodies on Phosphorylation of Tau-441 by MARK4
    Ziu, Iva
    Martic, Sanela
    FASEB JOURNAL, 2017, 31
  • [5] Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology
    Hou, Xu
    Watzlawik, Jens O.
    Cook, Casey
    Liu, Chia-Chen
    Kang, Silvia S.
    Lin, Wen-Lang
    DeTure, Michael
    Heckman, Michael G.
    Diehl, Nancy N.
    Al-Shaikh, Fadi S. Hanna
    Walton, Ronald L.
    Ross, Owen A.
    Melrose, Heather L.
    Ertekin-Taner, Nilufer
    Bu, Guojun
    Petrucelli, Leonard
    Fryer, John D.
    Murray, Melissa E.
    Dickson, Dennis W.
    Fiesel, Fabienne C.
    Springer, Wolfdieter
    ALZHEIMERS & DEMENTIA, 2021, 17 (03) : 417 - 430
  • [6] Elevated MARK2-Dependent Phosphorylation of Tau in Alzheimer's Disease
    Gu, Gucci Jijuan
    Wu, Di
    Lund, Harald
    Sunnemark, Dan
    Kvist, Alexander J.
    Milner, Roy
    Eckersley, Sonia
    Nilsson, Lars N. G.
    Agerman, Karin
    Landegren, Ulf
    Kamali-Moghaddam, Masood
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 33 (03) : 699 - 713
  • [7] Investigating MARK4 inhibitory potential of Bacopaside II: Targeting Alzheimer's disease
    Anwar, Saleha
    Mohammad, Taj
    Azhar, Md. Khabeer
    Fatima, Hera
    Alam, Afsar
    Hasan, Gulam Mustafa
    Islam, Asimul
    Kaur, Punit
    Hassan, Md. Imtaiyaz
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 245
  • [8] PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo
    Li, Fangfang
    Liu, Zongliang
    Sun, Heyuan
    Li, Chunmei
    Wang, Wenyan
    Ye, Liang
    Yan, Chunhong
    Tian, Jingwei
    Wang, Hongbo
    ACTA PHARMACEUTICA SINICA B, 2020, 10 (02) : 289 - 300
  • [9] PCC0208017,a novel small-molecule inhibitor of MARK3/MARK4,suppresses glioma progression in vitro and in vivo
    Fangfang Li
    Zongliang Liu
    Heyuan Sun
    Chunmei Li
    Wenyan Wang
    Liang Ye
    Chunhong Yan
    Jingwei Tian
    Hongbo Wang
    ActaPharmaceuticaSinicaB, 2020, 10 (02) : 289 - 300
  • [10] Inhibition of MARK4 by serotonin as an attractive therapeutic approach to combat Alzheimer's disease and neuroinflammation
    Shamsi, Anas
    DasGupta, Debarati
    Alhumaydhi, Fahad A.
    Khan, Mohd Shahnawaz
    Alsagaby, Suliman A.
    Al Abdulmonem, Waleed
    Hassan, Md. Imtaiyaz
    Yadav, Dharmendra Kumar
    RSC MEDICINAL CHEMISTRY, 2022, 13 (06): : 737 - 745
12345